Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030335220> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W3030335220 endingPage "554" @default.
- W3030335220 startingPage "551" @default.
- W3030335220 abstract "ObjectiveTo evaluate the efficacy and safety of argatroban in the treatment of progressive cerebral infarction.MethodsThree hundred hospitalized patients with progressive cerebral infarction from October 2006 to September 2011 were collected，among which 150 cases who agreed to the use of argatroban as experimental group，and 150 cases who didn’t agree to the use of argatroban for economic reasons as control group.Experimental group was treated with venous argatroban.It was 60 mg/d within the first 2 days and 24 h continuous intravenous drip.From the beginning of the 3rd day，the dosage was changed to 10 mg each time，twice a day for 5 days.Additionally，75 mg clopidogrel was given once a day for 12 days.Control group was only treated with 75 mg clopidogrel once a day for 14 days.The degree of neurological deficit was compared using the National Institutes of Health Stroke Scale (NIHSS) scoring and the rehabilitation condition was evaluated by Barthel index (BI) and modified Rankin Scale (mRS) scoring between 2 groups before treatment and 3 d，14 d，30 d and 90 d after treatment respectively，and further compared to patients with large artery stenosis and anterior or posterior circulation infarction.The indexes of coagulation function of 2 groups were monitored meanwhile.ResultsThe degree of neurological deficit was significantly improved in the short term (before treatment:NIHSS 15.19±2.70，after treatment of 3 d 10.75±2.09，t=2.114，P=0.037;14 d 8.77±1.50，t=2.092，P=0.039;30 d 6.89±0.79，t=2.520，P=0.013;90 d 4.85±0.38，t=2.723，P=0.008)，and the activities of daily living were significant enhanced in the experimental group (after treatment of 30 d BI 70.89±12.69，90 d 88.16±11.96，90 d mRS 1.57±0.39) when compared with the control group (after treatment of 30 d BI 60.26±11.85，t=2.292，P=0.023;90 d 69.90±12.63，t=2.790，P=0.006;90 d m RS 2.14±0.52，t=2.124，P=0.035).For large artery stenosis or posterior circulation infarction，the efficacy of argatroban was better.The indexes of coagulation function were in the normal range both before and after medication.No serious adverse reaction occurred during treatment.ConclusionArgatroban which has a higher security probably improves the prognosis and reduces the disability of patients with progressive cerebral infarction.Key words: Pipecolic acids; Brain infarction; Anticoagulants; Prognosis" @default.
- W3030335220 created "2020-06-05" @default.
- W3030335220 creator A5004214379 @default.
- W3030335220 creator A5036650726 @default.
- W3030335220 creator A5048194156 @default.
- W3030335220 date "2013-08-08" @default.
- W3030335220 modified "2023-09-25" @default.
- W3030335220 title "Clinical study on the efficacy and safety of argatroban in patients with progressive cerebral infarction" @default.
- W3030335220 doi "https://doi.org/10.3760/cma.j.issn.1006-7876.2013.08.014" @default.
- W3030335220 hasPublicationYear "2013" @default.
- W3030335220 type Work @default.
- W3030335220 sameAs 3030335220 @default.
- W3030335220 citedByCount "0" @default.
- W3030335220 crossrefType "journal-article" @default.
- W3030335220 hasAuthorship W3030335220A5004214379 @default.
- W3030335220 hasAuthorship W3030335220A5036650726 @default.
- W3030335220 hasAuthorship W3030335220A5048194156 @default.
- W3030335220 hasConcept C126322002 @default.
- W3030335220 hasConcept C127413603 @default.
- W3030335220 hasConcept C141071460 @default.
- W3030335220 hasConcept C2777292125 @default.
- W3030335220 hasConcept C2777798775 @default.
- W3030335220 hasConcept C2777849778 @default.
- W3030335220 hasConcept C2779450755 @default.
- W3030335220 hasConcept C2779612170 @default.
- W3030335220 hasConcept C2780645631 @default.
- W3030335220 hasConcept C2780931571 @default.
- W3030335220 hasConcept C2993523616 @default.
- W3030335220 hasConcept C3020199598 @default.
- W3030335220 hasConcept C42219234 @default.
- W3030335220 hasConcept C500558357 @default.
- W3030335220 hasConcept C541997718 @default.
- W3030335220 hasConcept C71924100 @default.
- W3030335220 hasConcept C78519656 @default.
- W3030335220 hasConcept C89560881 @default.
- W3030335220 hasConceptScore W3030335220C126322002 @default.
- W3030335220 hasConceptScore W3030335220C127413603 @default.
- W3030335220 hasConceptScore W3030335220C141071460 @default.
- W3030335220 hasConceptScore W3030335220C2777292125 @default.
- W3030335220 hasConceptScore W3030335220C2777798775 @default.
- W3030335220 hasConceptScore W3030335220C2777849778 @default.
- W3030335220 hasConceptScore W3030335220C2779450755 @default.
- W3030335220 hasConceptScore W3030335220C2779612170 @default.
- W3030335220 hasConceptScore W3030335220C2780645631 @default.
- W3030335220 hasConceptScore W3030335220C2780931571 @default.
- W3030335220 hasConceptScore W3030335220C2993523616 @default.
- W3030335220 hasConceptScore W3030335220C3020199598 @default.
- W3030335220 hasConceptScore W3030335220C42219234 @default.
- W3030335220 hasConceptScore W3030335220C500558357 @default.
- W3030335220 hasConceptScore W3030335220C541997718 @default.
- W3030335220 hasConceptScore W3030335220C71924100 @default.
- W3030335220 hasConceptScore W3030335220C78519656 @default.
- W3030335220 hasConceptScore W3030335220C89560881 @default.
- W3030335220 hasIssue "08" @default.
- W3030335220 hasLocation W30303352201 @default.
- W3030335220 hasOpenAccess W3030335220 @default.
- W3030335220 hasPrimaryLocation W30303352201 @default.
- W3030335220 hasRelatedWork W2225236003 @default.
- W3030335220 hasRelatedWork W2348126296 @default.
- W3030335220 hasRelatedWork W2349695266 @default.
- W3030335220 hasRelatedWork W2353442288 @default.
- W3030335220 hasRelatedWork W2357759546 @default.
- W3030335220 hasRelatedWork W2362190768 @default.
- W3030335220 hasRelatedWork W2374817173 @default.
- W3030335220 hasRelatedWork W2379369071 @default.
- W3030335220 hasRelatedWork W2379934834 @default.
- W3030335220 hasRelatedWork W2380914977 @default.
- W3030335220 hasRelatedWork W2382320711 @default.
- W3030335220 hasRelatedWork W2383475893 @default.
- W3030335220 hasRelatedWork W2384374197 @default.
- W3030335220 hasRelatedWork W2624850454 @default.
- W3030335220 hasRelatedWork W2978063543 @default.
- W3030335220 hasRelatedWork W3030977888 @default.
- W3030335220 hasRelatedWork W3031275184 @default.
- W3030335220 hasRelatedWork W3032101378 @default.
- W3030335220 hasRelatedWork W3032806964 @default.
- W3030335220 hasRelatedWork W3196730105 @default.
- W3030335220 hasVolume "46" @default.
- W3030335220 isParatext "false" @default.
- W3030335220 isRetracted "false" @default.
- W3030335220 magId "3030335220" @default.
- W3030335220 workType "article" @default.